Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
284lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
8 lessons
7mPolicyAdvanced
Why Emideltide (DSIP) Was the Only Peptide the Panel Did Not Recommend
The panel backed six peptide nominations but not Emideltide. Here is why evidence and identity questions mattered, and what the result means for people following sleep peptides.
7mPeptidesIntermediate
Epitalon After the Advisory Vote: Compounding Access and Evidence Gaps
Epitalon received a narrow advisory vote for 503A compounding in insomnia. That vote is not FDA approval, immediate access, or validation of longevity claims.
7mPeptidesIntermediate
KPV Peptide Guide: What It Is, Why It Matters After the 2026 Panel Vote
A beginner-friendly guide to KPV, its relationship to alpha-MSH, the evidence behind its nominated uses, and the limits of the 2026 PCAC recommendation.
7mResearchAdvanced
MOTS-c's 503A Recommendation: What Changed and What Did Not
MOTS-c now has a favorable advisory recommendation. It still does not have FDA drug approval or an open 503A compounding path.
7mPolicyAdvanced
After the PCAC Votes: Category 1 Interim Access vs Waiting for Rulemaking
PCAC recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for 503A compounding. The unresolved fight is what happens while FDA completes rulemaking.
7mPolicyAdvanced
Semax After the PCAC Recommendation: Access, Evidence, and What to Watch
The favorable Semax vote moved its compounding nomination forward, but the narrow result exposed unresolved questions about evidence, characterization, and US clinical use.
9mPolicyAdvanced
FDA's July 23 Peptide Panel Backed BPC-157, KPV, and TB-500. Here Is What Happens Next.
The FDA's peptide panel made its first moves on BPC-157, KPV, and TB-500. The vote matters, but the real story is what it changes next and what still has to happen before compounding pharmacies see any relief.
8mStart hereBeginner
503a vs 503b vs Unapproved Peptide Status: What's the Difference?
Confused about peptide compounding categories? This guide breaks down 503a compounding pharmacies, 503b outsourcing facilities, and why “research use only” is not a consumer pathway PeptIQ endorses.
Also available at /blog for legacy links.